Director adds 2,710 InspireMD (NSPR) shares in amended Form 4
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
InspireMD director Paul Stuka reported an open-market purchase of 2,710 shares of InspireMD common stock. The transaction occurred on December 9, 2025 at a weighted average price of $1.81 per share, in multiple trades between $1.80 and $1.81. Following this purchase, Stuka directly owned 391,628 shares. The Form 4/A amends a prior filing solely to correct the number of shares shown in one column, with no other changes.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,710 shares ($4,905)
Net Buy
1 txn
Insider
Stuka Paul
Role
Director
Bought
2,710 shs ($5K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 2,710 | $1.81 | $5K |
Holdings After Transaction:
Common Stock — 391,628 shares (Direct)
Footnotes (1)
- This Form 4/A amends the Form 4 filed on December 11, 2025 solely to correct the number of shares reported in Table I, Column 4. The number of shares reported in Column 5 was correct as originally filed. No other changes have been made. The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.80 to $1.81. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
FAQ
What insider transaction did InspireMD (NSPR) disclose in this Form 4/A?
InspireMD disclosed that director Paul Stuka purchased 2,710 shares of common stock in the open market. The transaction took place on December 9, 2025 at a weighted average price of $1.81 per share, executed through multiple trades within a narrow price range.
Why was this InspireMD (NSPR) Form 4/A filed as an amendment?
The Form 4/A was filed to correct the number of shares reported in Table I, Column 4 of the original Form 4. The filing states that Column 5, showing post-transaction holdings, was correct initially, and no other changes were made to the prior report.
What does the price range in the InspireMD (NSPR) Form 4/A footnote mean?
The footnote explains that the reported price is a weighted average across several trades. Individual transactions occurred at prices between $1.80 and $1.81 per share, and the reporting person offers to provide full trade-by-trade details upon request to interested parties or regulators.